Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges

AIDS

Volumn 21, Issue 14, 2007, Pages 1841-1848

  Rasmussen, Robert A ^a,b   Ong, Helena ^a   Song, Ruijiang ^a,b   Chenine, Agnès Laurence ^a,b   Ayash Rashkovsky, Mila ^a,b   Hu, Shiu Lok ^c   Polacino, Patricia ^c   Else, James G ^d   Novembre, Francis J ^d   Ruprecht, Ruth M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Animal model; HIV clade C; Multimeric gp160; Protein immunization; SHIV; Vaccine

Indexed keywords

DNA VACCINE; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PROTEIN HIV1084I; PROTEIN SHIV 1157IP; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENVELOPE GENE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS STRAIN;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; GENE PRODUCTS, GAG; GENE PRODUCTS, TAT; HIV ENVELOPE PROTEIN GP160; MACACA MULATTA; RNA, VIRAL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, SYNTHETIC; VIRAL LOAD; VIRAL PROTEINS;

EID: 34548232879     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32828684ea     Document Type: Article

References (25)

1. Report IAVI. International AIDS Vaccine Initiative Report. In: http://www.iavireport.org; 2006.
2. Song RJ, Chenine AL, Rasmussen RA, Ruprecht CR, Mirshahidi S, Grisson RD, et al. Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol 2006; 80:8729-8738.
3. Li JT, Halloran M, Lord CI, Watson A, Ranchalis J, Fung M, et al. Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol 1995; 69:7061-7067.
4. Rasmussen RA, Hofmann-Lehman R, Montefiori DC, Li PL, Liska V, Vlasak J, et al. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J Med Primatol 2002; 31:40-60.
5. Rasmussen RA, Hofmann-Lehmann R, Li PL, Vlasak J, Schmitz JE, Reimann KA, et al. Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8R T-cell-depleted macaques. AIDS 2002; 16:829-838.
6. Rasmussen RA, Montefiori DC, Robinson HL, McClure HM, Ruprecht RM. Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin. J Infect Dis 2001; 184:1603-1607.
7. Grisson RD, Chenine AL, Yeh LY, He J, Wood C, Bhat GJ, et al. Infectious molecular clone of a recently transmitted pediatric human immunodeficiency virus clade C isolate from Africa: evidence of intraclade recombination. J Virol 2004; 78:14066-14069.
8. Vlasak J, Ruprecht RM. AIDS vaccine development and challenge viruses: getting real. AIDS 2006; 20:2135-2140.
9. Rasmussen RA, Ong H, Kittel C, Ruprecht CR, Ferrantelli F, Hu SL, et al. DNA prime/protein boost immunization against HIV clade C: Safety and immunogenicity in mice. Vaccine 2006; 24:2324-2332.
10. Andre S, Seed B, Eberle J, Schraut W, Bultmann A, Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998; 72:1497-1503.
11. Klaniecki J, Dykers T, Travis B, Schmitt R, Wain M, Watson A, et al. Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus. AIDS Res Hum Retroviruses 1991; 7:791-798.
12. Haffar O, Garrigues J, Travis B, Moran P, Zarling J, Hu SL. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol 1990; 64:2653-2659.
13. Hu SL, Travis BM, Garrigues J, Zarling JM, Sridhar P, Dykers T, et al. Processing, assembly, and immunogenicity of human immunodeficiency virus core antigens expressed by recombinant vaccinia virus. Virology 1990; 179:321-329.
14. Polacino PS, Stallard V, Klaniecki JE, Pennathur S, Montefiori DC, Langlois AJ, et al. Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques. J Virol 1999; 73:8201-8215.
15. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312.
16. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905.
17. Hofmann-Lehmann R, Swenerton RK, Liska V, Leutenegger CM, Lutz H, McClure HM, Ruprecht RM. Sensitive and robust onetube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res Hum Retroviruses 2000; 16:1247-1257.
18. Semba RD, Kumwenda N, Hoover DR, Taha TE, Quinn TC, Mtimavalye L, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999; 180:93-98.
19. Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001; 75:5526-5540.
20. Beddows S, Schulke N, Kirschner M, Barnes K, Franti M, Michael E, et al. Evaluating the immunogenicity of a disul-fide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2005; 79:8812-8827.
21. Chakrabarti BK, Kong WP, Wu BY, Yang ZY, Friborg J, Ling X, et al. Modifications of the human i mmunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002; 76:5357-5368.
22. Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, Srivastava IK, et al. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 2006; 80:8745-8762.
23. Jeffs SA, Goriup S, Kebble B, Crane D, Bolgiano B, Sattentau Q, et al. Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. Vaccine 2004; 22:1032-1046.
24. Robinson WE Jr, Kawamura T, Gorny MK, Lake D, Xu JY, Matsumoto Y, et al. Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc Natl Acad Sci USA 1990; 87:3185-3189.
25. Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 2001; 75:1165-1171.